Prolacta Bioscience

Prolacta specializes in the collection, processing and sale of human milk-based products for premature infants

Prolacta Bioscience is a privately held company dedicated to Advancing the Science of Human Milk. The company is the world leader in providing human milk-based neonatal nutritional products for critically ill, premature infants in the neonatal intensive care unit (“NICU”) setting. The company's lead product, Prolact+, is the only human milk-derived fortifier and has been shown to improve clinical outcomes for premature infants and drive cost savings to the hospital. Prolacta also markets a number of other human milk-derived products in addition to developing a portfolio of innovative human milk-based products in its pipeline. The company is the industry leader in the quality and safety of nutritional products made from donor breast milk, and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human milk.

Transaction Summary

  • Essex Woodlands was the lead investor in the company's $35 million growth equity financing in November 2016.